PURPOSE: Patients with advanced, incurable thyroid cancer not amenable to surgery or radioactive iodine ((131)I) therapy have few satisfactory therapeutic options. This multi-institutional study assessed the activity and safety of axitinib, an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 in patients with advanced thyroid cancer. PATIENTS AND METHODS: Patients with thyroid cancer of any histology that was resistant or not appropriate for (131)I were enrolled onto a single-arm phase II trial to receive axitinib orally (starting dose, 5 mg twice daily). Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors was the primary end point. Secondary end points included duration of response, progression-free survival (PFS), overall survival, safety, and modulation of soluble (s) VEGFR. RESULTS: Sixty patients were enrolled. Partial responses were observed in 18 patients, yielding an ORR of 30% (95% CI, 18.9 to 43.2). Stable disease lasting > or = 16 weeks was reported in another 23 patients (38%). OBJECTIVE: responses were noted in all histologic subtypes. Median PFS was 18.1 months (95% CI, 12.1 to not estimable). Axitinib was generally well tolerated, with the most common grade > or = 3 treatment-related adverse event being hypertension (n = 7; 12%). Eight patients (13%) discontinued treatment because of adverse events. Axitinib selectively decreased sVEGFR-2 and sVEGFR-3 plasma concentrations versus sKIT, demonstrating its targeting of VEGFR. CONCLUSION: Axitinib is a selective inhibitor of VEGFR with compelling antitumor activity in all histologic subtypes of advanced thyroid cancer.
PURPOSE:Patients with advanced, incurable thyroid cancer not amenable to surgery or radioactive iodine ((131)I) therapy have few satisfactory therapeutic options. This multi-institutional study assessed the activity and safety of axitinib, an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 in patients with advanced thyroid cancer. PATIENTS AND METHODS: Patients with thyroid cancer of any histology that was resistant or not appropriate for (131)I were enrolled onto a single-arm phase II trial to receive axitinib orally (starting dose, 5 mg twice daily). Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors was the primary end point. Secondary end points included duration of response, progression-free survival (PFS), overall survival, safety, and modulation of soluble (s) VEGFR. RESULTS: Sixty patients were enrolled. Partial responses were observed in 18 patients, yielding an ORR of 30% (95% CI, 18.9 to 43.2). Stable disease lasting > or = 16 weeks was reported in another 23 patients (38%). OBJECTIVE: responses were noted in all histologic subtypes. Median PFS was 18.1 months (95% CI, 12.1 to not estimable). Axitinib was generally well tolerated, with the most common grade > or = 3 treatment-related adverse event being hypertension (n = 7; 12%). Eight patients (13%) discontinued treatment because of adverse events. Axitinib selectively decreased sVEGFR-2 and sVEGFR-3 plasma concentrations versus sKIT, demonstrating its targeting of VEGFR. CONCLUSION:Axitinib is a selective inhibitor of VEGFR with compelling antitumor activity in all histologic subtypes of advanced thyroid cancer.
Authors: Binodh DeSilva; Wendell Smith; Russell Weiner; Marian Kelley; JoMarie Smolec; Ben Lee; Masood Khan; Richard Tacey; Howard Hill; Abbie Celniker Journal: Pharm Res Date: 2003-11 Impact factor: 4.200
Authors: M Klein; E Picard; J M Vignaud; B Marie; L Bresler; B Toussaint; G Weryha; A Duprez; J Leclère Journal: J Endocrinol Date: 1999-04 Impact factor: 4.286
Authors: Tetsuichiro Inai; Michael Mancuso; Hiroya Hashizume; Fabienne Baffert; Amy Haskell; Peter Baluk; Dana D Hu-Lowe; David R Shalinsky; Gavin Thurston; George D Yancopoulos; Donald M McDonald Journal: Am J Pathol Date: 2004-07 Impact factor: 4.307
Authors: Samuel E Deprimo; Carlo L Bello; John Smeraglia; Charles M Baum; Dominic Spinella; Brian I Rini; M Dror Michaelson; Robert J Motzer Journal: J Transl Med Date: 2007-07-02 Impact factor: 5.531
Authors: D Chan; J W Tyner; W J Chng; C Bi; R Okamoto; J Said; B D Ngan; G D Braunstein; H P Koeffler Journal: Oncol Lett Date: 2012-01-20 Impact factor: 2.967
Authors: Keith C Bible; Vera J Suman; Michael E Menefee; Robert C Smallridge; Julian R Molina; William J Maples; Nina J Karlin; Anne M Traynor; Priya Kumar; Boon Cher Goh; Wan-Teck Lim; Ayoko R Bossou; Crescent R Isham; Kevin P Webster; Andrea K Kukla; Carolyn Bieber; Jill K Burton; Pamela Harris; Charles Erlichman Journal: J Clin Endocrinol Metab Date: 2012-07-06 Impact factor: 5.958
Authors: James I Geller; Elizabeth Fox; Brian K Turpin; Stuart L Goldstein; Xiaowei Liu; Charles G Minard; Rachel A Kudgus; Joel M Reid; Stacey L Berg; Brenda J Weigel Journal: Cancer Date: 2018-11-05 Impact factor: 6.860